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Abstract 
Background: Dendritic cells (DCs) rendered suppressive by treatment with mitomycin C and loaded with the 
autoantigen myelin basic protein demonstrated earlier their ability to prevent experimental autoimmune encepha-
lomyelitis (EAE), the animal model for multiple sclerosis (MS). This provides an approach for prophylactic vaccination 
against autoimmune diseases. For clinical application such DCs are difficult to generate and autoantigens hold the risk 
of exacerbating the disease.
Methods: We replaced DCs by peripheral mononuclear cells and myelin autoantigens by glatiramer acetate (Copax-
one®), a drug approved for the treatment of MS. Spleen cells were loaded with Copaxone®, incubated with mitomy-
cin C (MICCop) and injected into mice after the first bout of relapsing-remitting EAE. Immunosuppression mediated by 
MICCop was investigated in vivo by daily assessment of clinical signs of paralysis and in in vitro restimulation assays of 
peripheral immune cells. Cytokine profiling was performed by enzyme-linked immunosorbent assay (ELISA). Migra-
tion of MICCop cells after injection was examined by biodistribution analysis of 
111Indium-labelled MICCop. The number 
and inhibitory activity of CD4+CD25+FoxP3+ regulatory T cells were analysed by histology, flow cytometry and in vitro 
mixed lymphocyte cultures. In order to assess the specificity of MICCop-induced suppression, treated EAE mice were 
challenged with the control protein ovalbumin. Humoral and cellular immune responses were then determined by 
ELISA and in vitro antigen restimulation assay.
Results: MICCop cells were able to inhibit the harmful autoreactive T-cell response and prevented mice from further 
relapses without affecting general immune responses. Administered MICCop migrated to various organs leading to an 
increased infiltration of the spleen and the central nervous system with CD4+CD25+FoxP3+ cells displaying a sup-
pressive cytokine profile and inhibiting T-cell responses.
Conclusion: We describe a clinically applicable cell therapeutic approach for controlling relapses in autoimmune 
encephalomyelitis by specifically silencing the deleterious autoimmune response.
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Background
Multiple sclerosis (MS) is a chronic inflammatory demy-
elinating disease of the central nervous system. Although 
many aspects of the etiology and pathogenesis of disease 
have not been exhaustively clarified, there is no doubt 
that the immune system plays a major role in the brain-
damaging process [1]. Several therapeutic tools offer the 
possibility of inhibiting the immune response, thus con-
trolling the pathogenic process of multiple sclerosis. This 
however, happens at the expense of an undifferentiated 
immunosuppression leading to side effects [2].
Special attention merit novel promising approaches, 
such as treatment of MS patients with fumarates or 
laquinimod. Dimethylfumarate was effective in both MS 
and psoriasis [3, 4]. Recent studies by Ghoreschi et  al. 
showed that improvement of diseases occurs by induc-
tion of type II dendritic cells (DCs) which produce IL-10 
instead of IL-12 and IL-23 [5]. Laquinimod strongly 
reduced infiltration of CD4+  and CD8+  T cells in the 
central nervous system and prevented relapses of EAE in 
mice. Based on observations in mice and humans Jolivel 
et  al. hypothesized that this beneficial effect was medi-
ated by DCs [6]. A couple of therapeutic attempts envis-
age the suppression of the brain-damaging attack without 
affecting the remaining immune response [7]. These 
strategies include: administration of attenuated autore-
active T cells, T-cell receptor peptide vaccination, DNA-
vaccination, treatment with altered peptide ligands, 
vaccination against axonal growth inhibitors associated 
with myelin or the use of DCs pulsed with specific anti-
gens [7].
Our previous animal studies showed that incubation 
of DCs with the chemotherapeutic agent mitomycin 
C (MMC) can convert these strongly stimulatory cells 
into suppressive cells. In a rat heart transplant model, 
pretreatment of recipients with donor DCs incubated 
with MMC induced suppression of allograft rejection 
[8]. In an attempt to explore whether this approach is 
also applicable to prevention of autoimmune diseases, 
syngeneic DCs were loaded with myelin basic protein 
(MBP), an autoantigen derived from the brain, incubated 
with MMC and then injected into mice [9]. The animals 
became resistant to subsequently induced experimental 
autoimmune encephalomyelitis (EAE), demonstrating 
that autoantigen-loaded, MMC-treated DCs can be used 
as a protective vaccine in autoimmune diseases—a find-
ing which is in line with other observations [10]. Here, we 
now address the question whether autoantigen-loaded 
suppressive cells might also be used for the therapy of an 
ongoing disease.
In a clinical setting the described cell therapeutic 
approach would raise some critical points. Injection of 
MBP or other autoantigens to a patient with MS entails 
the risk of exacerbating the disease. In the 1970s, a ran-
dom copolymer of amino acids, termed “glatiramer 
acetate” (GA; Copaxone®, Cop), was initially devel-
oped to mimic the composition of MBP [11]. Studies 
revealed that this copolymer has various targets within 
the immune response, among others interfering with 
T-cell reactions against some myelin antigens, such as 
MBP or proteolipid protein (PLP) [12–14]. In clinical tri-
als, Cop slowed the progression of disability and reduced 
the relapse rate of MS [15, 16] eventually resulting in its 
approval for the treatment of relapsing-remitting MS. 
Based on all these findings, the brain autoantigen—one 
hazardous component of our cell therapeutic—was 
replaced with Cop.
Moreover, naive DCs—the cells loaded with autoanti-
gens—are strongly stimulatory cells, and even if rendered 
suppressive, they might regain their stimulatory capac-
ity in  vivo, thus leading to an activation of the disease. 
Apart from the risk of immunostimulation, generation of 
DCs is rather time-consuming, expensive and difficult to 
standardize. Therefore, we replaced DCs with syngeneic 
PBMCs—cells which are less immunogenic and much 
easier to prepare.
In the present work, the therapeutic properties of Cop-
loaded MMC-induced peripheral blood mononuclear 
cells (MICCop) were analyzed in mice with EAE. The find-
ings pave the way for targeted immunosuppression in 
patients with MS and other autoimmune diseases.
Methods
Animals and EAE model
SJL/J mice (females, 6–8  weeks of age; haplotype H-2s) 
were purchased from Charles River Laboratories 
(Sulzfeld, Germany) and Janvier Labs (Le Genest-Saint-
Isle, France) and kept at the Interfacultary Biomedical 
Research Facility (IBF) of the University of Heidelberg 
(Heidelberg, Germany). SJL/J mice were used for an EAE 
model of relapsing-remitting disease after administra-
tion of immunogenic proteolipid protein (PLP) peptide 
PLP139–151. Mice received a standard rodent diet and 
water ad  libitum. During EAE experiments, food pellets 
as well as wet food and water (also supplied as water gel 
pouches) were placed on the floor of the cages as soon 
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as clinical paralytic signs had been observed. The project 
was approved by the Animal Welfare Board of the Gov-
ernmental Office (Karlsruhe, Germany) and the Univer-
sity of Heidelberg Committee for Ethics on Laboratory 
Animal Experimentation and was performed in com-
pliance with institutional guidelines, the German law 
for animal protection, the Directive 2010/63/EU of the 
European Union on the protection of animals used for 
scientific purposes and FELASA (Federation of European 
Laboratory Animal Science Associations, Ispwich, UK) 
guidelines and recommendations.
Induction of EAE and clinical assessment
EAE was actively induced according to previously pub-
lished protocols [17]. Emulsions for immunization were 
prepared by homogeneously combining complete Fre-
und’s adjuvant (CFA), a generated mixture of incomplete 
Freund’s adjuvant (IFA) and Mycobacterium tuberculo-
sis H37RA at 8  mg/mL (both from Difco Laboratories, 
Detroit, MI, USA), with equal volumes of myelin-derived 
peptide solution using glass syringe extrusion. Female 
SJL/J mice (8–10 weeks old) were immunized with 100 μg 
PLP139–151 (HCLGKWLGHPDKF) peptide (Peptide Syn-
thesis Core Facility, German Cancer Research Center). 
Mice were shortly anaesthetized using 2–3  % (v/v) iso-
flurane (Baxter, Unterschleissheim, Germany) and 50 µL 
of the antigen/CFA emulsion was injected subcutane-
ously (s.c.) into two semi-lateral thoracic sites. Clinical 
signs were evaluated daily in a blinded fashion according 
to a standard EAE grading scale: 0, no signs; 1, limp tail 
or hind limb weakness; 2, limp tail and hind limb weak-
ness or weakness of both hind limbs; 3, complete hind 
limb paralysis; 4, quadriplegia; and 5, moribund or death. 
Animals showing clinical signs in between these grades 
were scored intermediate using half increments [17]. 
Mice were euthanized by CO2 inhalation when reaching 
a score of 4.5 or at the end of the experiment.
Experimental treatment design
Treatment of disease was performed during the first 
remission phase. Only those mice were included into the 
experimental groups which showed at least a score of 3 in 
the acute phase and had a score of 1 or 0 on the two con-
secutive days before cellular treatment. Dependent on 
the course of disease, therapy started between day 20 and 
22 post immunization by injection of 2 × 107 cells (sus-
pended in 100 µL PBS w/o Ca2+/Mg2+) into the tail vein 
on each of three consecutive days. Administration of PBS 
into EAE mice served as control. Mice were assigned to 
the various treatment groups to obtain a similar distribu-
tion of mice within all groups regarding the course of the 
EAE disease as well as the current degree of clinical signs. 
One day prior to cell therapy, splenocytes (SPCs) were 
isolated from mice which had been immunized with the 
EAE-inducing peptide-CFA emulsion at the same time 
as those mice assigned to the different treatment groups. 
The majority of animals serving as cell donors showed 
clinical signs of disease of various degrees, whereas only 
very few did not exhibit any symptoms after EAE induc-
tion. Harvested SPCs were pooled before treatment. 
Donor mice with a similar distribution of clinical EAE 
scores were chosen for each of the three consecutive 
treatment days.
Immunization with ovalbumin
After successful treatment of EAE mice with MICCop, 
the animals were immunized s.c. with 100 μL ovalbumin 
(OVA)/IFA emulsion (Hooke Laboratories, Lawrence, 
MA, USA) on day 55 and boosted on day 74 post EAE 
induction.
Naïve as well as PBS-treated EAE-induced mice were 
included as controls. Mice were sacrificed 33 or 37 days 
after the last OVA immunization. Anti-OVA antibody 
titers in serum and OVA-specific T-cell proliferation of 
lymph node cells and SPCs were analyzed.
Preparation of serum and cells from peripheral lymphoid 
organs
After mice were sacrificed by CO2 inhalation, whole 
venous blood was collected and allowed to clot at room 
temperature. The clot was removed by centrifugation and 
serum was subsequently stored at −20  °C. Spleen and 
lymph nodes were retrieved, disintegrated mechanically 
and filtered through a 70-μm nylon Falcon® cell strainer 
(Corning Life Sciences, Amsterdam, The Netherlands). 
After washing the cells with PBS (PromoCell, Heidelberg, 
Germany) lysis of erythrocytes was performed for SPCs 
by suspending the pelleted SPCs in 0.2 % NaCl for 30  s 
followed by two wash steps with culture medium, con-
sisting of RPMI 1640 (PromoCell) supplemented with 
10  % FCS (Lonza, Cologne, Germany), 100  U/mL Peni-
cillin/100 μg/mL Streptomycin (PAA, Coelbe, Germany), 
1  % l-glutamine (PAA) and 50  μM β-mercaptoethanol 
(Carl Roth, Karlsruhe, Germany).
Generation of autoantigen‑loaded splenocytes, treatment 
with MMC and UV/C irradiation
Freshly isolated SPCs (5 × 106/mL in 12-well plates) were 
incubated o/n with or without 10 µg/mL glatiramer ace-
tate (GA, Copaxone®, Cop; Teva Pharma, Kirchzarten, 
Germany) in culture medium. Cells were harvested on 
ice the next day and washed with culture medium. After-
wards the cells were either treated with mitomycin C 
(MMC; medac, Wedel, Germany), UV/C-irradiated or left 
untreated. For MMC treatment, 5 ×  106 SPCs/mL were 
incubated in 50 µg MMC/mL for 30 min in a humidified 
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incubator (37  °C, 5  % CO2) and subsequently washed 
twice. UV/C irradiation was performed directly after 
antigen-loading (in 12-well-plates) in a Stratalinker 1800 
device (Stratagene, Santa Clara, CA, USA) using 25  mJ/
cm2. The cells were harvested on ice and washed twice.
Isolation of regulatory T lymphocytes (Tregs)
Pooled single cell suspensions of SPCs and lymph node 
cells (LNCs), herein referred to as peripheral blood mon-
onuclear cells (PBMCs) were obtained from EAE mice 
2  weeks after immunosuppressive therapy with MICCop 
as described above. Regulatory CD4+CD25+ T lym-
phocytes (Tregs) were purified by consecutive negative 
isolation of CD4+ cells and positive selection of CD25+ 
lymphocytes using a MACS® magnetic microbead kit as 
specified by the manufacturer (Miltenyi Biotec, Bergisch 
Gladbach, Germany), usually resulting in a purity above 
90  % of the CD4+CD25+ cell population. Importantly, 
initial flow cytometric examination revealed that nearly 
all (>95 %) CD4+CD25+ lymphocytes also expressed the 
transcription factor FoxP3.
Cellular assays, cytokine expression and antibody 
detection
For proliferation and cytokine secretion assays, SPCs and 
LNCs were isolated from treated mice. Cells were seeded 
in U-bottom 96-well plates (Greiner, Frickenhausen, Ger-
many) at 2  ×  105  cells/well in 200  µL culture medium 
and stimulated with either phytohemagglutinin (PHA) 
(Remel, Lenexa, USA) at 45  µg/mL or reactivated with 
5–20 µg/mL PLP139–151, Cop or 10 µg/mL OVA (chicken; 
Sigma-Aldrich, Taufkirchen, Germany). For analyses of 
T-cell proliferation, after 48 or 72  h, cells were pulsed 
with [3H]-thymidine (Hartmann Analytic, Braunschweig, 
Germany) at 1 µCi/well for further 18 h, harvested onto 
filter plates and [3H]-thymidine incorporation was meas-
ured in an automated β-counter (Inotech Biosystems, 
Rockville, MD, USA).
For assessment of cytokine expression, supernatants 
were obtained after 72 h of culture. The cytokines IL-2, 
IL-4, IL-6, IL-10, IL-12, IL-17, interferon-γ (IFN-γ), and 
transforming growth factor-β (TGF-β) and tumor necro-
sis factor-α (TNF-α) were quantified by enzyme-linked 
immunosorbent assay (ELISA) using commercial kits 
according to the manufacturer’s instructions (eBiosci-
ence, Frankfurt, Germany).
For cellular inhibition assays, 5 × 104 PBMCs per well 
were stimulated with PHA (45  µg/mL) and cocultured 
with 1 ×  104 isolated CD4+CD25+ Tregs (5:1 ratio) for 
72  h followed by incubation with [3H]-thymidine. Cell 
populations with and without PHA stimulus served as 
controls.
In addition, isolated CD4+CD25+ Tregs as well as con-
ventional CD4+ effector T lymphocytes (4  ×  105/well) 
were stimulated for 48 h with plate-bound hamster-anti-
mouse-CD3 mAb (10  µg/mL, clone 145-2C11; BD Bio-
sciences, Heidelberg, Germany). Supernatants were 
obtained and concentration of IL-10 was determined by 
ELISA (eBioscience).
Anti-OVA antibodies (Abs) were detected in serum 
from treated and OVA-immunized mice using a mouse 
anti-OVA ELISA kit according to the manufacturer’s 
instruction (Hooke Laboratories). Optical density of 
assay samples was measured photometrically in a micro-
plate reader (Tecan, Maennedorf, Switzerland) and 
cytokine concentrations and anti-OVA Ab titers were 
calculated by means of the respective standards.
Flow cytometric analysis of cellular markers and viability
Approximately 1  ×  106 SPCs were washed in PBS and 
blocked for 10 min on ice with 1 μg mouse BD Fc block 
CD16/CD32 (BD Biosciences) in 100  µL FACS-buffer, 
PBS containing 0.1 % bovine serum albumin (BSA; Carl 
Roth), and then incubated with PE-conjugated anti-
mouse-CD4 mAb (clone RM4–5, rat IgG2a, κ) as well 
as FITC-conjugated anti-mouse CD25 mAb (clone 3C7, 
rat IgG2b, κ) or their corresponding isotype controls (BD 
Biosciences) for 15  min at 4  °C in the dark. For further 
intracellular detection of the transcription factor Foxp3, 
cells were fixed, permeabilized and stained with rat-anti-
FoxP3 antibody (clone FJK-16 s; eBioscience). Cell viabil-
ity was determined with 7-aminoactinomycin D (7-AAD) 
and Annexin V (BD Biosciences). Cells were examined 
using a FACSCalibur™ flow cytometer (BD Biosciences) 
and data were analyzed with CellQuest™ Pro software 
(BD Biosciences).
Histological examination
The spine was dissected, immediately embedded into 
Tissue-Tek® (Sakura Finetek, Zoeterwoude, The Neth-
erlands) and frozen on dry ice. Specimens were stored 
at −80  °C until further analysis. Seven µm-thick sec-
tions of the lumbar region were cut on a cryostat, air-
dried and post-fixed in acetone. Sections were blocked 
with 5  % BSA (PAA) and 3  % mouse serum (Sigma-
Aldrich) in PBS for 30  min and then incubated with 
the primary antibody directed against FoxP3 (clone 
FJK-16  s; eBioscience) diluted 1:4800 in 1  % BSA solu-
tion at 4 °C overnight. The next day, sections were incu-
bated with biotin-conjugated rabbit anti-rat IgG (1:400) 
(Dako, Hamburg, Germany) in 1  % BSA solution at 
RT for 40  min followed by Neutravidin-Dylight549 
(Thermo Scientific, Waltham, MA, USA) at 1:500 dilu-
tion in washing solution (TBS  +  0.05  % Tween® 20). 
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Counterstaining of cellular nuclei was performed by 
incubation with Hoechst 33,342 (1:1000 in washing 
solution; Thermo Scientific). Sections were analyzed on 
a Zeiss Axioskop 50 epifluorescence microscope using 
Carl Zeiss Plan-NEOFLUAR 109/0.30 and 409/1.30 
objectives and Carl Zeiss filter sets No. 1 (excitation 
BP 365/12, emission LP 397) and No. 15 (excitation BP 
546/12, emission 590 nm) for detection of fluorescence. 
Digital images were acquired using a Leica DFC350FX 
camera and software.
Biodistribution studies for in vivo tracking 
of 111Indium‑labelled MICs
MICCop (4–5 ×  107) from naïve SJL/J mice were gener-
ated as described and labeled with 20  MBq 111Indium 
(In)-oxine (Mallinckrodt Pharmaceuticals, Dublin, Ire-
land) in PBS for 15  min at room temperature. After 
removal of free 111In-oxine by washing with 50 mL PBS, 
the cells were resuspended in 130 µL PBS and 50 µL of 
cell suspension was injected into the tail vein of recipi-
ent mice. Twenty-four hours later, mice were anaesthe-
tized with 1 % (v/v) sevoflurane (Baxter) and, after blood 
samples had been taken from the vena cava, perfusion 
with Ringer’s solution (B.Braun, Melsungen, Germany) 
was conducted until blood was completely washed out 
from the organ system. Tissue samples of organs were 
harvested and weighed. Radioactivity of the specimen 
was measured along with 10  µL-aliquots (n =  3) of the 
injected suspension in a γ-counter (LB951G, Berthold 
Technologies, Bad Wildbad, Germany). For each sample, 
the activity of the 111In-tracer in 1 g of tissue was calcu-
lated in relation to the originally injected total dose (% 
ID/g).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
5.0 (GraphPad Software, La Jolla, CA, USA) and IBM 
SPSS predictive analytics software (IBM, Armonk, NY, 
USA). Results were assessed by applying Student’s t test 
or ANOVA when normal Gaussian distribution was 
given. In contrast, the nonparametric Mann–Whitney U- 
or Fisher’s exact test was used for comparison of distri-
bution-free data sets, not covered by normal distribution. 
The limit of statistical significance was p ≤ 0.05 whereas 
a p value of  <  0.05 was considered to be significant (*), 
a p value of  <  0.01 highly significant (**) and a p value 
of < 0.001 extremely significant (***).
Results
Mitomycin‑induced cells loaded with Copaxone® (MICCop) 
reduce relapses of ongoing remitting‑relapsing EAE
We generated MICCop cells by loading syngeneic spleen 
cells (SPCs) in vitro with Cop and incubating them with 
MMC. In a series of experiments (Fig.  1a) the effect of 
MICCop was analyzed in a relapsing-remitting form of 
EAE. The disease was induced via PLP in SJL/J mice and 
2  weeks later the peak of paralysis was achieved. One 
week later the animals entered into remission. SPCs 
of syngeneic EAE animals were collected and used for 
preparation of MICCop. The cells were injected on three 
Fig. 1 MICCop reduce relapses of ongoing disease in remitting-relaps-
ing EAE. A relapsing-remitting EAE was induced in female SJL/J mice 
at day 0 with injection of proteolipid peptide PLP139–151 in complete 
Freund’s adjuvant. Clinical signs were evaluated daily. For cellular 
treatment, SPCs were isolated from EAE animals, cultured in vitro 
o/n with or without 10 µg/mL glatiramer acetate (GA, Copaxone®, 
Cop). On the day of cell therapy, splenocytes were either treated 
with 50 µg/mL MMC or UV/C-irradiated with 25 mJ/cm2. During first 
remission, animals of treatment groups received 2 × 107 cells on each 
of three consecutive days (days 21–23): a MMC-treated SPCs (MICs; 
n = 7, dark grey diamonds), Cop-loaded and MMC-treated SPCs  
(MICCop; n = 7, black triangles) or PBS (control; n = 6, white squares); b 
Cop-loaded and UV/C-irradiated SPCs (UVC-SPCCop; n = 15, grey cir-
cles) or PBS (control; n = 15, white squares). Each panel shows the time 
course of the mean EAE score for the respective treatment group
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consecutive days. In contrast to untreated controls (white 
squares), treated animals showed nearly no relapses 
(black triangles). Interestingly, when injecting SPCs incu-
bated with MMC only (MIC), a similar albeit weaker 
inhibition was noted (dark grey diamonds).
For clinical application one important objective is the 
prevention of further relapses. Table 1 shows that MICCop 
therapy reduces the number of relapses from 70.5 % (con-
trol) to 16.7 % (p < 0.0001). The duration of relapse is also 
significantly reduced (median duration from 20  days in 
the control to 4  days in the MICCop group, p =  0.017). 
In contrast, MIC therapy neither reduced the number of 
relapses (p = 0.66) nor their duration (p = 0.063) when 
compared to PBS-treated controls. Its suppressive effect 
(number of relapses) was significantly weaker than in the 
MICCop group (p = 0.045) but was not different in respect 
to the duration of relapse (p = 0.476).
It is known that Cop per se already inhibits EAE [18, 19]. 
Therefore, we addressed the question whether SPCs incu-
bated with Cop only (without MMC) also have an inhibi-
tory action. The findings demonstrated (Table  1) that 
they significantly reduce the rate (p = 0.026) but not the 
duration of relapse (p = 0.266). In both cases the suppres-
sive effect was significantly weaker than that of MICCop 
(p < 0.0001 and p = 0.024, respectively).
UV‑induced apoptotic cells loaded with Copaxone® do not 
prevent relapses of ongoing EAE
MMC is a chemotherapeutic drug, which induces apop-
tosis in tumor cells [20]. Our studies showed that the 
same happens with murine SPCs when incubated with 
MMC (% apoptotic cells 3, 6, 12, 18, 24, and 30  h after 
incubation with MMC: 1.8, 3.6, 12.2, 46.1, 67.3 and 
82.9). This raised the question whether apoptosis might 
be responsible for the observed immunosuppression. In 
a follow-up experiment, apoptotic cells were generated 
by UV/C irradiation. An equivalent number of apop-
totic cells (corresponding to that obtained via MMC) 
loaded with Cop was injected into sick mice. In contrast 
to MICCop treatment, no inhibition of disease was noted 
(Fig. 1b grey circles). On the contrary, UVC-SPCCop cells 
increased the number of relapses from 70.5  % (control) 
to 100  % (p =  0.034) and their duration (median) from 
20 days (control) to 24 days (p = 0.755) (Table 1).
Suppression induced by MICCop therapy is 
autoantigen‑specific
A series of therapeutic agents can control EAE in mice 
or MS in humans, but many of them exert an unspecific 
immunosuppressive action. We addressed the question 
whether MICCop therapy suppresses only the deleteri-
ous immune response against the central nervous system 
(CNS), while preserving other immune responses.
In one experiment lymphocytes derived from lymph 
nodes or spleens of EAE mice having received MICCop- or 
control-therapy were re-stimulated in vitro with various 
concentrations of PLP—the disease-inducing autoanti-
gen. The experiment depicted in Fig. 2 shows that periph-
eral T lymphocytes of MICCop-treated animals (white 
triangles) did not respond to PLP, in contrast to those 
of PBS-treated control mice (black squares). This dem-
onstrates suppression of the autoantigen-specific T-cell 
response. No response to MBP84-104 and MOG92-106 
was detected even in untreated EAE mice, showing that 
Table 1 Incidence and duration of paralytic relapses in EAE mice after cell treatment
Treatment groups were compared using Fisher’s exact test (incidence of relapse) and One-tail Mann–Whitney U test (duration of relapse): * p < 0.05, ** p < 0.01, 
*** p < 0.001
CI confidence interval; EAE experimental autoimmune encephalomyelitis; MIC mitomycin C-induced cells; MICCop Copaxone
®-loaded mitomycin C-induced cells; PBS 
phosphate-buffered saline; SD standard deviation; SPCCop Copaxone
®-loaded splenocytes; UVC-SPCCop Copaxone®-loaded ultraviolett C-irradiated splenocytes
a Incidence of relapse: number of mice with relapse (total number of animals) in treatment group
b Incidence of relapse MICCop vs. control, *** p < 0.0001; MIC vs. control, p = 0.66; SPCCop vs. control, * p = 0.026; UVC-SPCCop vs. control, * p = 0.034; MICCop vs. MIC, 
* p = 0.045; MICCop vs. SPCCop, *** p < 0.0001; MICCop vs. UVC-SPCCop, * p = 0.016; MIC vs. SPCCop, p = 1.00; MIC vs. UVC-SPCCop, * p = 0.022; SPCCop vs. UVC-SPCCop, 
** p = 0.006
c Duration of relapse MICCop vs. control, * p = 0.017; MIC vs. control, p = 0.063; SPCCop vs. control, p = 0.266; UVC-SPCCop vs. control, p = 0.755; MICCop vs. MIC, 
p = 0.476; MICCop vs. SPCCop, * p = 0.024; MICCop vs. UVC-SPCCop, ** p = 0.005; MIC vs. SPCCop, p = 0.107; MIC vs. UVC-SPCCop, * p = 0.026; UVC-SPCCop vs. SPCCop, 
p = 0.945
Treatment group Incidence of relapsea, b Relapse rate (%) Duration of relapsec
Median Mean ± SD CI (95 %)
Control (PBS) 31 (44) 70.5 20.0 17.0 ± 9.6 13.6–20.4
MICCop 5 (30) 16.7 4.0 6.6 ± 5,0 2.2–11.0
MIC 4 (7) 57.1 6.5 9.50 ± 8.4 1.3–17.7
SPCCop 8 (15) 53.3 13.5 14.5 ± 6,6 9.9–19.1
UVC-SPCCop 15 (15) 100 24.0 19.6 ± 7.7 15.7–23.5
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epitope-spreading from PLP to MBP and MOG did 
not take place during progression of disease (data not 
shown). Next, we wanted to see what the cytokine pat-
tern of these non-responding lymphocytes derived from 
MICCop-treated animals looks like when the cells are 
exposed to PLP or Cop. As shown in the experiment 
presented in Fig.  3a–d, SPCs and LNCs produce more 
IL-10, whereas LNCs also secrete more TGF-β than cells 
of untreated EAE animals. No differences were noted 
regarding the expression of IL-2, IL-4, IL-6, IL-12, IFN-
γ, TNF-α and only partially increased expression of IL-17 
was observed (data not shown).
In a second series of experiments the immune response 
to foreign antigens of EAE mice treated with MICCop was 
studied. The animals were immunized with ovalbumin 
(OVA) (Fig. 4a). As controls served PBS-treated EAE- or 
naïve mice immunized with OVA. Antibody as well as 
T-cell responses against OVA were measured. As shown 
in Fig.  4b, the antibody response of diseased animals 
was not influenced by MICCop-treatment. Regarding T 
cells, although the MICCop-treatment seemed to slightly 
inhibit the response to OVA, the suppression was statis-
tically not significant (Fig. 4c). The immune response of 
MICCop-treated animals to PLP, however, was still absent 
after OVA immunization (Fig.  4d; relative proliferation 
of EAE  +  OVA vs. EAE  +  MICCop  +  OVA after 48  h, 
**p  <  0.01, 72  h, *p  <  0.05 and 96  h, **p  <  0.01). Taken 
together, these findings show that MICCop-treated EAE 
mice can develop an immune response to third party 
antigens, whereas the response to the disease-inducing 
autoantigen remains suppressed.
MICCop cells migrate into the spleen and other organs
Our previous findings showed that allogeneic MICs 
injected into rats migrate mainly into the spleen, 
leading to a locally increased infiltration with 
CD4+CD25+FoxP3+ Tregs [21]. This prompted us to 
analyze whether syngeneic MICCop cells labeled with 
111Indium have a similar fate when injected into mice. As 
shown in Fig. 5 this was the case.
Treatment of EAE mice with MICCop increases the 
CD4+CD25+FoxP3+ cell infiltration of peripheral lymphoid 
organs and the central nervous system
Spleens of MICCop-treated EAE mice were collected, 
cells prepared and analyzed by flow cytometry. As 
shown in Fig.  6a (middle panel) MICCop treatment led 
to an increased number of CD4+CD25+FoxP3+ cells as 
compared to treatment with UV-induced apoptotic cells 
(right panel) or PBS (left panel). Statistics are shown in 
panel B.
Next, we addressed the question whether MICCop treat-
ment increases the infiltration of the CNS—the target of 
the autoimmune attack—with CD4+CD25+FoxP3+cells. 
The results show that this is indeed the case. Panel C 
shows representative histological sections of the spinal 
cord from MICCop-treated and control mice, and panel D 
the statistical representation of these findings.
CD4+CD25+FoxP3+ cells exhibit an immunosuppressive 
activity
We examined whether the infiltrating 
CD4+CD25+FoxP3+ cells have suppressive activ-
ity. CD4+CD25+FoxP3+ cells were obtained by MACS 
separation from spleen and lymph nodes of MICCop- 
treated animals. Syngeneic T cells from PBS-
treated EAE animals were stimulated with PHA and 
CD4+CD25+FoxP3+ cells added to the culture. Figure 7a, 
b shows that CD4+CD25+FoxP3+ cells inhibit the poly-
clonal T-cell response, thus proving their suppressive 
Fig. 2 MICCop therapy suppresses the PLP-specific T-cell response. 
SJL/J mice were induced to exhibit clinical signs of EAE. In their first 
phase of remission, on days 21–23 post disease induction, mice were 
treated with MICCop (white triangles) or PBS (control, black squares). 
LNCs (a) and SPCs (b) of MICCop-treated (n = 8) and control (n = 9) 
EAE mice were harvested on day 49 after disease induction. Cells 
of each treatment group were restimulated in vitro with PLP139–151 
for 48 h at the indicated concentrations (abscissa). Proliferation 
was determined by [3H]-thymidine incorporation and is displayed 
as x-fold increase in relation to unstimulated cells (ordinate). The 
mean ± standard error of the mean (SEM) of a sixtuplicate setup was 
calculated. One representative of three independent experiments is 
shown. Unpaired Student’s t test was performed for comparison of 
the treatment groups (*p < 0.05; **p < 0.01; ***p < 0.001)
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potential. Thereafter, IL-10 cytokine expression of 
CD4+CD25+FoxP3+ cells was analyzed (Fig. 7c). The result 
shows an increased production of this immunomodula-
tory cytokine as compared to conventional T cells (Tcons).
Discussion
Broad immunosuppression has been the standard ther-
apy for autoimmune diseases during the past half century. 
The main drawback of this therapy is the lack of distinc-
tion between harmful responses to self-antigens and use-
ful responses to foreign antigens. Recently, a series of 
novel therapeutic options aiming at re-establishing spe-
cific tolerance of the derailed autoimmune response have 
been conceived (reviewed by [22]).
Apart from chemical or biologic therapeutics, such as 
monoclonal antibodies, four main cell-based therapies 
for the induction of tolerance in autoimmune diseases are 
currently under investigation: hematopoietic chimerism, 
mesenchymal stromal cells (MSCs), Tregs and DCs [22]. 
Establishing a hematopoietic chimerism, although effec-
tive in some cases, remains a quite invasive intervention, 
difficult to implement into clinical routine [23]. Although 
treatment with MSCs initially seemed to be safe and pos-
sible improvement of disease was noted [24–28], recent 
observations showing that MSCs might differentiate into 
sarcoma cells [29] or protect breast cancer cells through 
Tregs [30] question their application. Ex vivo expansion 
of Tregs also poses problems when it comes to clinical 
application, such as the inclusion of harmful effector T 
cells [31] or the possible abolition of the suppressive phe-
notype following injection into patients. Moreover, as 
shown recently, Tregs might promote metastatic spread 
of mammary cancer cells [32]. A series of studies showed 
that tolerogenic DCs (tolDCs) can be used for controlling 
autoimmune diseases in animal models [10]. However, 
their use for the treatment of autoimmune disorders in 
humans is still in its infancy [10, 33]. The main challenge 
in bringing tolDCs into the clinic is the requirement to 
preserve their tolerogenic property upon transfusion into 
the patient.
Major drawbacks of almost all therapies are the labo-
rious and time-consuming process of cell production as 
well as the high costs. In the present article, we describe 
a therapy which suppresses specifically the harmful 
immune response against the CNS and is based on sup-
pressive cells which can be easily and quickly generated. 
Moreover, the cells are stable and can be prepared in 
large amounts at rather moderate costs.
Fig. 3 Cytokine expression of peripheral lymphocytes from MICCop-treated EAE mice after in vitro-restimulation with PLP and Copaxone
®. Sple-
nocytes (SPCs; left column) and lymph node cells (LNCs; right column) were isolated from PBS- (control, black, n = 9) and MICCop-treated (MICCop, 
grey, n = 8) EAE mice and restimulated in vitro with 20 µg/mL PLP139-151 or Copaxone® (Cop). After 72 and 96 h, supernatants were collected and 
concentrations of TGF-β (a and b) and IL-10 (c and d) were determined by ELISA. Unstimulated cells represent basic cytokine expression. The 
mean ± standard error of the mean (SEM) was calculated for values measured in duplicate. Treatment groups were compared using unpaired 
Student’s t test (***p < 0.001; **p < 0.01; *p < 0.05; ns, not significant)
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Fig. 4 MICCop therapy does not suppress the immune response to foreign antigens. a MICCop- (n = 8) or PBS-treated (n = 8) EAE mice were immu-
nized with ovalbumin (OVA) on day 55 and 74 after disease induction. Additional controls comprised healthy animals with OVA (naïve + OVA, n = 4) 
and w/o OVA immunization (naïve w/o OVA, n = 2). Animals were sacrificed on days 107 and 111. Serum was obtained and peripheral mononuclear 
cells from lymph nodes (LNCs) were isolated. b Anti-OVA antibodies were detected by ELISA in sera of single animals diluted 2500 to 312,000-fold. 
The graph shows mean values ± standard deviation (SD). For comparison of the different groups with the naïve w/o OVA control the unpaired 
Student’s t test was used (***p < 0.001). c and d OVA- and PLP-specific T-cell proliferation of LNCs harvested from single animals was assessed by 
in vitro restimulation with OVA protein (c) and PLP139–151 (d). Proliferation was determined after 48, 72 and 96 h by [
3H]-thymidine incorporation and 
is indicated as x-fold increase in relation to unstimulated cells (ordinate). Shown is the mean ± standard error of the mean (SEM) of every group. The 
differences of T-cell responses towards OVA among the groups naïve + OVA, EAE + OVA and EAE + MICcop + OVA were statistically not significant 
( c) whereas the proliferative response of MICCop-treated mice upon PLP stimulation was still suppressed after OVA immunization ( d; EAE + MICCOP  
+ OVA vs. EAE + OVA after 48 h: p < 0.01; 72 h: p < 0.05; 96 h: p < 0.01). As control, LNC proliferation against OVA of naïve mice immunized with OVA 
was significantly stronger than that of naïve mice without OVA treatment (96 h: p < 0.01). Two-way-ANOVA test with Bonferroni correction was used
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An elegant cell therapeutic approach conceptually close 
to ours, which has already been tested in phase-1 trial, is 
the use of autologous peripheral blood mononuclear cells 
chemically coupled with seven peptides derived from 
myelin proteins [34]. This model is based on the pioneer-
ing work of S.D. Miller in animals [35]. Previous obser-
vations demonstrated that MBP-like peptides can lead to 
an exacerbation of the disease [36]. What distinguishes 
our model from the one above is, among others, the 
lack of use of potentially harmful autoantigens. Instead, 
Copaxone®—an approved MS-protecting drug—is used. 
A second component of our cell therapeutic is MMC—a 
well-known drug, which has been used for decades in 
cancer patients [37].
It is known that GA competes with MBP for binding 
to MHC-II on antigen-presenting cells and for its rec-
ognition by specific T cells [13]. GA also displaces PLP 
from the MHC binding site, inhibits PLP-specific T-cell 
responses and PLP-induced EAE [14, 38]. When prepar-
ing MICCop we loaded the cells with Cop. Therefore, the 
question must be addressed whether MICCop cells owe 
their therapeutic effect to the injected dose of Cop. What 
argues against this reasoning is the finding that untreated 
or UV-treated spleen cells loaded with this drug did not 
reduce the rate of relapses. UVC-SPCCop even enhanced 
the course of disease. Moreover, the dose of Cop used for 
preparing MICCop was 0.040 mg per 2 × 107 cells (num-
ber of injected cells), of which only a small fraction was 
taken up by the cells. Even if the whole amount of Cop 
would have been loaded onto cells, it would have been far 
lower than the therapeutic dose which lies in the range of 
2 mg/mouse [38].
MMC is a chemotherapeutic agent and as such might 
induce side effects in patients. Therefore, the question 
must be addressed whether the amount of MMC con-
tained in the MIC cell preparation might cause harm to 
patients. The therapeutic dose of MMC is 10–20 mg/m2. 
This would amount to 63–126 µg per mouse. Upon incu-
bation of cells and subsequent washing, undetectable con-
centrations of MMC were noted (detection limit 0.13 µg/
ml). No side effects are expected under these conditions. 
Another critical point might be the possible malignant 
transformation of cells after MMC-treatment. MIC cells, 
however, cannot further divide and enter into apoptosis. 
Both preclude side effects upon injection into the patient.
Previous studies showed that apoptotic cells might 
either stimulate or suppress the immune response, their 
regulatory effect depending on a series of factors, nota-
bly on the type of immunologically active molecules co-
expressed with apoptosis [20]. Because MMC induces 
apoptosis in murine SPCs, this might provide an expla-
nation for the immunosuppressive activity of MICCop. 
Fig. 5 Tracking of injected MICCop cells in mice. SPCs from naïve SJL/J mice were loaded with Copaxone
® (Cop) o/n and then treated with  
50 µg/mL MMC (MICCop). 2 × 107 MICCop were labeled with 20 MBq 111Indium (In)-oxine and injected into the tail vein of the recipient mouse. 
Twenty-four hours later the animals were euthanized, thoroughly perfused with Ringer’s solution and single organs were harvested and weighed. 
The activity of tissue samples as well as of an aliquot of the administered labeled cell suspension was determined for each animal in a γ-counter and 
calculated as  % of total injected dose (ID) per gram tissue. Shown is the in vivo distribution of activity in the indicated organs of four mice depicted 
as mean ± SD (LN lymph node)
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However, when injecting Cop-loaded SPCs rendered 
apoptotic by UV irradiation, no inhibition of disease was 
noted. A similar observation was made in our rat heart 
allograft model upon treatment of recipients with apop-
totic donor cells [21]. Because apoptosis is an irrevers-
ible process, administration of MICCop cells, which are 
underway to apoptosis, would preclude their return to a 
stimulatory status in a clinical setting.
When applied to MS patients, autologous cells can be 
harvested by cytapheresis, loaded with Cop and treated 
with MMC. To mimic this process in the present experi-
mental study, SPCs of syngeneic sick mice were used 
for preparation of MICs. Interestingly, cells treated with 
MMC (without Cop or PLP) already showed a certain 
inhibitory effect. It is known that antigen-presenting cells 
from peripheral lymphoid organs of MS patients carry 
brain autoantigens [39, 40]. The same applies to antigen-
presenting cells of EAE animals [39]. This observation 
might explain why treatment with MMC (without addi-
tional loading with Cop as a surrogate of autoantigen) 
confers suppressive properties. If MMC-treated cells 
without Cop already have a suppressive activity, the ques-
tion must be addressed, why they should be loaded with 
Cop. When evaluating the effectiveness of MIC therapy, 
three parameters must be taken into account: the degree 
of paralysis, the number of animals suffering relapses 
as well as the duration of relapses. Regarding the mean 
degree and duration of paralysis, the difference between 
MIC and MICCop was apparently modest. However, when 
considering the number of mice with paralytic attacks, 
the difference between MIC and MICCop becomes 
evident.
Fig. 6 Treatment of EAE mice with MICCop increases CD4
+CD25+FoxP3+ cell infiltration of peripheral lymphoid organs and the central nervous 
system. The infiltration with CD4+CD25+FoxP3+ regulatory T cells (Tregs) of peripheral lymphoid organs (a and b) and the central nervous system (c 
and d) of cell-treated and control EAE mice was determined with FACS analysis in SPCs and immunohistochemistry in spinal cord sections, respec-
tively. a For FACS analysis SPCs of animals treated with PBS (control), MICCop and UVC-SPCCop were isolated 4 weeks after cell therapy and stained 
with fluorescence-labeled antibodies and the corresponding isotype controls. One representative FACS-plot is shown for each group representing 
the expression of CD25 and FoxP3 in CD4+ cells. b Tregs within SPCs of each treatment group were quantified and are depicted as percentage 
of CD4+CD25+FoxP3+ T cells within the CD4+ T-cell population (mean value ± SEM; n = 8 per group). Data were statistically compared with the 
unpaired Student’s t test (*p < 0.05). c Immunohistochemistry of the lumbar spinal cord for evaluation of infiltrating Tregs was performed on snap-
frozen tissue of PBS- and MICCop-treated animals. After incubation of tissue sections with anti-FoxP3-antibody, Tregs were visualized with biotin-con-
jugated rabbit anti-rat IgG and Neutravidin-Dylight549. Cellular nuclei were counterstained with Hoechst 33,342 (blue). Digital fluorescence images 
were obtained at ×40 magnification and the number of infiltrated Tregs (pink) was determined. Scale bars depict 50 µm. d Statistical analysis of 
evaluated sections based on values from single animals (n = 8 for each group) was performed using Mann–Whitney U test (*p < 0.05). Mean values 
of FoxP3+ cells per mm2 ± SEM are presented
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Along with the control of relapses, induction of anti-
gen-specific suppression is the most relevant property of 
MICCop cell therapy. Treated mice responded normally 
to OVA and even to myelin autoantigens such as MBP 
or MOG. In a clinical setting this would allow to control 
the inflammatory process in the brain without affecting 
the remaining immune response. The question arose why 
the immune response to PLP but not to MBP and MOG 
was suppressed by MICCop. As already mentioned, Cop 
has the ability to interact with PLP-specific T cells [14]. 
When injecting MICCop into EAE mice already sensitized 
to PLP (but not to MBP and MOG) the administered cells 
would be recognized first by highly affine PLP-specific 
T cells. This provides an explanation for the suppressed 
brain-damaging immune response against PLP.
While the mechanism of immunosuppression induced 
by MICCop has not been exhaustively clarified, a cou-
ple of observations point to an involvement of Tregs 
in mediation of suppression. Their number increased 
in the spleen and CNS following injection of MICCop. 
We speculate that upon injection, MICCop migrate into 
peripheral lymphoid organs, where they convert con-
ventional PLP-specific T cells into CD4+CD25+FoxP3+ 
Tregs, which then migrate into the CNS. There, as well as 
in lymphoid organs, they produce suppressive cytokines, 
such as IL-10, unspecifically inhibiting the local immune 
reaction. The latter point is supported by our observation 
that CD4+CD25+FoxP3+ Tregs suppress the polyclonal 
T-cell response in  vitro. Similar Tregs were also found 
in untreated EAE animals as a general regulatory mech-
anism of the immune response [41, 42]. However, their 
number was significantly lower than in treated mice. It 
seems that in untreated animals deleterious T cells pre-
vail, whereas in MICCop-treated animals Tregs control 
the scenario. Apart, from CD4+CD25+FoxP3+ other 
regulatory cell subsets may play their roles and should be 
envisaged in future studies.
Conclusions
Donor MIC cell therapy is currently being implemented 
in living donor kidney transplantation [21]. The findings 
of the present study, although not clarifying all mechanis-
tic questions, constitute a sound basis for a clinical phase 
I study with MICCop cells in patients with MS.
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